Related Experiment Video
Updated: May 15, 2026
09:45
Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines
Published on: August 21, 2019
Small cell lung cancer
Journal of the National Comprehensive Cancer Network : JNCCN
|January 12, 2013
Summary
Small cell lung cancer (SCLC) is a common neuroendocrine tumor, often diagnosed at an advanced stage. While chemotherapy offers initial symptom relief and survival benefits for extensive-stage SCLC, long-term survival remains rare, emphasizing the need for smoking cessation.
Area of Science:
- Oncology
- Pulmonology
- Cancer Research
Background:
- Small cell lung cancer (SCLC) represents approximately 15% of all lung cancers and is a type of neuroendocrine tumor.
- Extensive-stage SCLC is more prevalent than limited-stage disease and is the primary focus of these clinical practice guidelines.
- SCLC is initially responsive to treatment, but disease recurrence is a common cause of mortality.
Purpose of the Study:
- To provide NCCN Clinical Practice Guidelines for the management of extensive-stage small cell lung cancer (SCLC).
- To outline current therapeutic strategies and recommendations for patients with extensive-stage SCLC.
Main Methods:
- Guidelines based on current evidence and expert consensus for SCLC management.
- Focus on treatment approaches for extensive-stage disease, considering its higher incidence.
Main Results:
- Chemotherapy can effectively palliate symptoms and extend survival in most patients with extensive-stage SCLC.
- Despite initial treatment response, long-term survival rates for extensive-stage SCLC remain low due to disease recurrence.
Conclusions:
- SCLC is strongly linked to cigarette smoking, underscoring the critical importance of smoking cessation interventions.
- Current treatment paradigms for extensive-stage SCLC, primarily chemotherapy, offer palliative benefits but limited long-term cures.